Literature DB >> 9365152

New model of colon interposition following distal gastrectomy in rats.

Y Sato1, S Ohwada, Y Morishita.   

Abstract

An interposed colon segment has been clinically used as a gastric substitute following an esophagogastric resection for benign or malignant esophageal and gastric cardia disease. The purpose of this study is to establish a rat model of colonic interposition following distal gastrectomy and to investigate its serial mucosal changes. About 80% of the glandular stomach was resected, and a 3-cm segment of the transverse colon interposed isoperistaltically between the remnant stomach and duodenum. Epithelial proliferation and aberrant crypt foci in the interposed colon segment were investigated serially. Crypt lengths in the interposed colon increased significantly (P < 0.05) compared to the remnant colon. The number of goblet cells per crypt per 1 mm in the interposed colon also decreased significantly (P < 0.05) compared to the remnant colon. A PCNA labeling index (LI) of the remnant colon was almost 30%. A PCNA LI in the interposed colon at 4, 8, and 12 months after surgery was 30.8%, 31.8%, and 47.8%, respectively. The PCNA LI in the interposed colon increased significantly (P < 0.05) 12 months after surgery compared to the remnant colon at 4, 8, and 12 months after surgery. Aberrant crypt foci were not detected in the interposed colon segment. In conclusion, we established a rat model of colonic interposition following distal gastrectomy. The interposed colon mucosa adapted well. Long-term mucosal changes of the interposed colon segment should now be studied.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365152     DOI: 10.1023/a:1018899308242

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Long-term endoscopic and flow cytometric follow-up of colon interposition.

Authors:  H Lindahl; R Rintala; H Sariola; I Louhimo
Journal:  J Pediatr Surg       Date:  1992-07       Impact factor: 2.545

2.  Morphological effects of transposing a segment of transverse colon into the ileum of the Holtzman rat.

Authors:  W H St Clair; C A Stahlberg; J W Osborne
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1984

3.  Use of the colon segment as a gastric substitute after total gastrectomy.

Authors:  Y Nagamachi; K Ishihara
Journal:  Am J Proctol Gastroenterol Colon Rectal Surg       Date:  1982-08

4.  Effects of 1,2-symmetrical dimethylhydrazine on jejunocolic transposition in Sprague-Dawley rats.

Authors:  C Celik; A Mittelman; N S Paolini; D Lewis; J T Evans
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

5.  Gastric hyperplastic changes and thymidine uptake after partial gastrectomy in rats.

Authors:  M Fazi; P Bechi; R Naspetti; G Caderni; A Amorosi; P Dolara
Journal:  Hepatogastroenterology       Date:  1991-10

6.  Duodenal reflux through the pylorus induces gastric adenocarcinoma in the rat.

Authors:  K Miwa; H Hasegawa; T Fujimura; H Matsumoto; R Miyata; T Kosaka; I Miyazaki; T Hattori
Journal:  Carcinogenesis       Date:  1992-12       Impact factor: 4.944

7.  Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine.

Authors:  E Mereto; L Frencia; M Ghia
Journal:  Cancer Lett       Date:  1994-01-15       Impact factor: 8.679

8.  The effect of chenodeoxycholic acid on the development of aberrant crypt foci in the rat colon.

Authors:  L A Sutherland; R P Bird
Journal:  Cancer Lett       Date:  1994-01-30       Impact factor: 8.679

9.  Colon interposition for esophageal disease: histologic finding of colonic mucosa after a follow-up of 5 months to 15 years.

Authors:  J Isolauri; H Helin; H Markkula
Journal:  Am J Gastroenterol       Date:  1991-03       Impact factor: 10.864

10.  Characterisation of aberrant crypt foci in carcinogen-treated rats: association with intestinal carcinogenesis.

Authors:  G Caderni; A Giannini; L Lancioni; C Luceri; A Biggeri; P Dolara
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.